Skip to main content
BF Biosciences Limited logo

BF Biosciences Limited — Investor Relations & Filings

Ticker · BFBIO ISIN · PK0148201012 PSX Manufacturing
Open in API
Filings indexed 33 across all filing types
Latest filing 2025-10-03 AGM Information
Country PK Pakistan
Listing PSX BFBIO

About BF Biosciences Limited

http://bfbio.com/

BF Biosciences Limited is a pioneering biotech pharmaceutical company engaged in the import, manufacturing, marketing, and distribution of pharmaceutical products. The company specializes in state-of-the-art biotechnology, offering life-saving drugs for conditions such as cardiovascular diseases, breast cancer, diabetes mellitus, chronic kidney diseases, and rheumatoid arthritis. Operating as a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina, BF Biosciences serves markets including Pakistan, Nepal, Afghanistan, and other international regions, built upon a foundation of trust and credibility.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting
AGM Information Classification · 100% confidence The document is a detailed notice of an Annual General Meeting (AGM) for BF Biosciences Limited, including the agenda, procedures for participation, proxy voting, and special business items such as approval of related party transactions. It contains no financial statements or detailed financial analysis itself but rather serves as an official notification and instructions for the AGM. The document length is substantial but it is clearly a meeting notice and not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R).
2025-10-03 English
Notice of Annual General Meeting prior to publication
Regulatory Filings
2025-10-02 English
Financial Results for the Year Ended 30-06-2025
Regulatory Filings
2025-09-23 English
Transmission of Quarterly Report for the Period Ended 2025-03-31
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Information For The Nine Months Ended 31 March 2025' and contains detailed financial statements including statement of financial position, profit or loss, comprehensive income, changes in equity, cash flows, and notes. It covers a period shorter than a full fiscal year (nine months) and includes substantive financial data and management commentary. The presence of un-audited interim financial statements and the period specified clearly indicate this is an interim or quarterly financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the appropriate classification is 'Interim / Quarterly Report (IR)'.
2025-04-30 English
Financial Results for the Quarter Ended 2025-03-31
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including a Condensed Interim Statement of Financial Position, Profit or Loss, Comprehensive Income, Changes in Equity, and Cash Flows for the nine months and quarter ended 31 March 2025. The presence of unaudited interim financial data and the specific period covered (nine months and quarter) indicates this is a periodic financial report shorter than a full fiscal year. The document length is substantial (12,270 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-04-29 English
Quarterly Progress Report for the Period Ended December 31, 2024
Regulatory Filings
2025-04-11 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.